Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways

被引：0
|
作者：
Fei Wang
Chong Yuan
Bo Liu
Yan-Fang Yang
He-Zhen Wu
机构：
[1] Hubei University of Chinese Medicine,Faculty of Pharmacy
[2] Key Laboratory of Traditional Chinese Medicine Resources and Chemistry of Hubei Province,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
Syringin; (Rupr. & Maxim.) Harms; Breast cancer; Hub genes; Bioinformatics; Mechanism of action;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways
    Wang, Fei
    Yuan, Chong
    Liu, Bo
    Yang, Yan-Fang
    Wu, He-Zhen
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [2] The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment
    Gao, Lanyang
    Zhu, Lei
    Shen, Chen
    Hou, Xiaoming
    Chen, Youyou
    Zou, Linglin
    Qiang, Huiyan
    Teichmann, Alexander T.
    Fu, Wenguang
    Luo, Yao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [3] Gomisin N Exerts Anti-liver Cancer Effects and Regulates PI3K-Akt and mTOR-ULK1 Pathways in Vitro
    Zhu, Pei-Li
    Lam, Dick Fai
    Li, Jun-Kui
    Fu, Xiu-Qiong
    Yin, Cheng-Le
    Chou, Ji-Yao
    Wang, Ya-Ping
    Liu, Yu-Xi
    Chen, Ying-Jie
    Wu, Jia-Ying
    Wu, Ying
    Bai, Jing-Xuan
    Liang, Chun
    Yu, Zhi-Ling
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2020, 43 (08) : 1267 - 1271
  • [4] Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation
    Mano, MS
    Awada, A
    Minisini, A
    Durbecq, V
    Di Leo, A
    Piccart, M
    BREAST, 2004, 13 (04): : 347 - 349
  • [5] Recent Developments in Targeted Therapies of the RAF-MEK and PI3K-AKT Pathways in Cancer Treatment
    Cremers, Lobke G. M.
    Boonstra, Johannes
    CURRENT CANCER THERAPY REVIEWS, 2012, 8 (03) : 205 - 217
  • [6] Tocotrienols Target PI3K/Akt Signaling in Anti-Breast Cancer Therapy
    Sylvester, Paul W.
    Ayoub, Nehad M.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (07) : 1039 - 1047
  • [7] RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction
    Zhong, Jian
    BIOLOGICAL CHEMISTRY, 2016, 397 (03) : 215 - 222
  • [8] Fibroblast growth factor 18 exerts anti-osteoarthritic effects through PI3K-AKT signaling and mitochondrial fusion and fission
    Yao, Xudong
    Zhang, Jiaming
    Jing, Xingzhi
    Ye, Yaping
    Guo, Jiachao
    Sun, Kai
    Guo, Fengjing
    PHARMACOLOGICAL RESEARCH, 2019, 139 : 314 - 324
  • [9] Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Saini, Kamal S.
    Loi, Sherene
    de Azambuja, Evandro
    Metzger-Filho, Otto
    Saini, Monika Lamba
    Ignatiadis, Michail
    Dancey, Janet E.
    Piccart-Gebhart, Martine J.
    CANCER TREATMENT REVIEWS, 2013, 39 (08) : 935 - 946
  • [10] Itraconazole exerts anti-liver cancer potential through the Wnt, PI3K/AKT/mTOR, and ROS pathways
    Wang, Wenping
    Dong, XiaoXv
    Liu, Yi
    Ni, Boran
    Sai, Na
    You, Longtai
    Sun, Mingyi
    Yao, Yu
    Qu, Changhai
    Yin, Xingbin
    Ni, Jian
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 131
12345